A new genetic study found another explanation, Yale University researchers report July 5 in the journal Neuron.

A team from the University of California, San Francisco, devised a new electroporation-based CRISPR-Cas9 method, eliminating viruses from the gene editing process and laying the groundwork for safer, more precise and more efficient editing for CAR-T cancer treatments and other cell therapies.

In a 10-patient cohort study led by Dr. Jean Roy, hematologist and professor at the Faculty of Medicine of Université de Montréal, that aims to understand how to mitigate the risks associated with the treatment of multiple myeloma, a malignant cancer, researchers have adopted an innovative approach based on the unique immunological properties of umbilical cord blood in an effort to improve the safety and efficiency of allografting, the preferred treatment for this disease.

The FDA approved an investigational new drug application from Cellectis for a Phase 1 clinical trial of UCART22, its third gene-edited CAR-T cell candidate.

Christiana Care has been talking with the U.S. Food & Drug Administration about developing a gene editing tool called CRISPR to assist in lung cancer treatments. One question they?ll face in the future is if insurance companies will pick up the cost.

Award? goes to biochemists Virginijus Siksnys, whose lab independently developed the gene-editing tool, Emmanuelle Charpentier and Jennifer Doudna.

For more information, you can visit the festival?s website at: stemcellfestival.com

In research published today in the journal Cell Stem Cell, scientists at Columbia University Vagelos College of Physicians and Surgeons present the most definitive evidence to date that the human brain makes new neurons throughout life.

A new Japanese joint venture company called MAGiQ Therapeutics ? the result of a collaboration between Q Therapeutics and Reprocell ? aims to develop cell and gene therapies for demyelinating and degenerative diseases of the central nervous system.

The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) ? a CAR-T cell therapy ? for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).